西格玛集团

2023年5月5日

阿历克斯基翁5月5日,2023年以1590万美元从一系列一轮融资,Durham-based启动Ten63专注于发展管道无药可治first-in-class小分子针对目前癌症的目标。系列所得将用于推进公司的管道的小分子,包括其铅Myc抑制剂程序。公司的管道是由其专有计算药物发现平台,被称为之外,其目的是综合搜索超过100万亿可行的分子,使一线和最佳治疗的发展,该公司在其声明指出。杜克和TTIC衍生公司总部设在Research Triangle Park, Ten63超出平台使公司“设计有效的化学对最困难的目标通过搜索以前未知的,药物类,综合化学空间访问。“超越超级有效结合了物理和人工智能搜索算法。这使企业追求验证生物目标超过传统的治疗研究,Ten63说。该公司的主要目标是原癌基因,细胞中的基因表达的调节。一半以上的癌症是由原癌基因放松管制,该公司表示。它在癌症中的作用已经在20000多个出版物指出在过去的40年。尽管如此,无药可治原癌基因仍然是一个目标。Ten63认为其计算平台有可能破解Myc之外,无药可治以及其他致癌基因,将景观对病人的治疗。 “Using BEYOND, we have found a new pocket and path forward in drugging c-Myc. Our novel compound is 10x more potent than the best literature compounds,” Ten63 announced on its website. Ten63 isn’t the only company taking aim at c-Myc. Aptose Biosciences, Omega Therapeutics, Allogene Therapeutics and others have developed assets aimed at this target. The impetus behind Ten63 began with the cancer diagnosis of Gilda Szacher Frenkel, the mother of company co-founder and chief executive officer Marcel Frenkel. Frenkel’s cancer was driven by mutations to proteins that regulate cellular processes. Although their roles were well known, those proteins were undruggable by current methods, Marcel Frenkel said. “Ten63 has set out with a vengeance to change this paradigm through the application of next-generation computational drug discovery methods,” Frenkel said in a statement. Mark Hallen, a company cofounder and chief technology officer of Ten63, said the BEYOND platform builds on molecular voxel theory (MVT). “MVT allows BEYOND to explore a chemical space of over 100 trillion compounds, with mathematical guarantees to discover the best small molecule solutions given the company’s state-of-the-art hybrid AI/physics-based models. BEYOND also enables Ten63 to find novel pockets and binding sites, as well as a large diversity of chemical matter,” Hallen said in a statement. In addition to Frenkel and Hallen, Ten63’s leadership team includes a team of seasoned pharma industry veterans and computational experts. Among them are co-founder Nancy Miller-Rich, who was previously global head of BD and Strategy at Merck; and Melissa Epstein, head of IP Strategy. Epstein was previously a Senior Vice President at Novartis. Stephen Thompson, formerly a section head at GSK and research fellow at Vertex, serves as Head of Chemistry. Charles Holst, Ten63’s Vice President and Head of Biology, was previously a senior director at Ribometrix and senior principal scientist at Pfizer. The Series A was led by Hatteras Venture Partners. Other participants include Morpheus Ventures, SOSV, Draper Associates, Alexandria Venture Investments, the Sigma Group and other unnamed investors. Clay Thorp, co-founder and general partner at Hatteras Venture Partners said Ten63 and its team have taken AI and machine learning driven drug discovery to the next level. The Ten63 approach will opens the doors to an “expanded universe of compounds and binding pockets,” said Thorp, who is chairman of the Ten63 Board of Directors. Frenkel expressed his gratitude to the venture firms backing the company and its mission to crack undruggable targets. “At Ten63, we are dedicated to developing groundbreaking therapeutics that benefit patients, and we are pleased to strengthen our syndicate with the experience and expertise to help us get there. Our investors have repeatedly demonstrated the ability to help companies grow to have a positive impact on patients’ lives. We look forward to building on that tradition,” Frenkel said. About the Author